Biogen stock rallies after full-day halt as FDA panel recommends Alzheimer’s drug for approval

Breaking News

Biogen Inc.

shares rallied in the extended session late Friday following a full-day halt after the biotech company received a recommendation from a Food and Drug Administration advisory committee to approve an Alzheimer’s treatment it makes with Eisai Co.

Biogen shares rallied as much as 9% after hours, after spending the regular session halted at $308.88. Eisai shares finished Friday up 9.4% at $81.03. On Friday, the FDA’s Peripheral and Central Nervous System Drugs Advisory Committee voted unanimously to recommend the companies’ drug Leqembi to treat Alzheimer’s disease. While the FDA is not bound to committee recommendations, the agency generally follows them. Approval of the drug is expected by July 6.

Original Post

Articles You May Like

Time to Buy These Affordable Tech Stocks for More Upside
UAW launches union campaigns at Tesla, 12 other automakers in the U.S.
Singapore once again the world’s most expensive city to live in: EIU
IRobot’s stock sinks after European regulators express concerns about Amazon deal
Ancient Bitcoin Whale Awakens and Moves Thousands of BTC By U.Today

Leave a Reply

Your email address will not be published. Required fields are marked *